Bacteria engineered to treat liver disease
US11439673B2 · kind B2 · utility
0Cited by
1References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 31, 2019 |
| Grant date | Sep 13, 2022 |
| Priority date | — |
| Expiry date | May 31, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides genetically engineered bacteria that are capable of reducing excess ammonia and converting ammonia and/or nitrogen into alternate byproducts. The invention also provides pharmaceutical compositions comprising the genetically engineered bacteria, and methods of modulating and treating disorders associated with excess ammonia and inflammation in the gut and the liver, including, for example, hepatic encephalopathy, NASH/NAFLD, HCV, and Huntington's disease, in a subject, comprising administering the engineered bacterium to the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.